Pharmacogenomics and the Potential for Utilization of Testing Results for Patient Care in the Cardiac Surgical Intensive Care Unit

Overview

About this study

The overall goals of this pilot study are to: (1) describe pharmacogenomics (PGx) testing results and identify PGx variants that may inform treatment regimens and symptom management in cardiac surgical patients with an ICU stay, and (2) describe cardiac critical care team members’ awareness and attitudes towards the applications of pharmacogenomics testing results for their practice before and after completion of a PGx education module.
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Adults scheduled for cardiovascular surgery with an anticipated ICU stay

  • Patient age ≥ 18
  • Mayo Clinic patient with a scheduled Cardiac surgery
  • Patient must provide own written informed consent and written HIPAA authorization prior to initiation of any study-related procedures

Cardiac critical care team members

  • Cardiac surgeons
  • RN caring for patients in the cardiac surgical intensive care unit
  • Pharmacists caring for patients in the cardiac surgical intensive care unit
  • NPs and PAs caring for patients in the cardiac surgical intensive care unit
  • Intensivists caring for patients in the cardiac surgical intensive care unit

Exclusion Criteria: 

Adults scheduled for cardiovascular surgery with an anticipated ICU stay

  • Patient age < 18
  • Scheduled ventricular assist device (VAD) implantation
  • Known pregnancy
  • Patient with uncontrolled concurrent illness including documented psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly provide informed consent (i.e., documented dementia)
  • Surgery occurring less than 24 hours from potential consent time (to allow for PGx test turnaround time of 24 hours)

Cardiac critical care team members

  • Providers not caring for patients having cardiac surgery with a stay in the cardiac surgical intensive care unit

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Linda Chlan, Ph.D., R.N.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20418901

Mayo Clinic Footer